Hims & Hers
Consumer telehealth platform with subscription-based treatment and fulfilment.
Available information varies by company and source.
Profile record updated:
Company facts
- Official name
- Hims & Hers Health, Inc.
- Entity type
- COMPANY
- Founded
- 2017
- Headquarters
- 2261 Market Street, Suite 483, San Francisco, CA 94114
- Company size
- 1,001–5,000
- Market role
- B2C Consumer App / Platform
- Ticker
- HIMS
- Official website
- himsandhers.com
What Hims & Hers does
Hims & Hers operates a vertically integrated digital healthcare marketplace and service platform for consumers. It acquires demand through branded consumer channels, routes users through digital intake and licensed-provider review, converts eligible users into prescription or treatment plans, and captures downstream value through pharmacy fulfilment, recurring medication delivery, and ongoing care management. The model creates value by reducing friction in access to routine and sensitive care categories, while increasing lifetime value through subscriptions, cross-sell into adjacent conditions, and improved treatment matching supported by proprietary clinical interaction data.
Category differentiation
Hims & Hers is a consumer telehealth and prescription fulfilment platform, not a pure SaaS vendor or a general hospital provider. Its AI capability supports internal clinical workflows rather than functioning as a standalone foundation model business.
Strategic context
AI-supported assessment from the existing company research; distinguish interpretation from sourced facts.
Hims & Hers Health, Inc. is a publicly listed consumer health company operating a direct-to-consumer telehealth platform. It connects patients with licensed healthcare providers through a digital workflow covering intake, consultation, prescribing, fulfilment, home delivery, and ongoing follow-up. Its core offers span sexual health, mental health, dermatology, weight management, hormone therapy, diagnostics, and women’s health. The business serves consumers directly under the Hims and Hers brands and uses its proprietary MedMatch system internally to support treatment matching and care personalisation. The company generates revenue primarily from recurring subscription care plans that bundle consultations, prescriptions, medication delivery, and ongoing treatment management. Additional revenue comes from one-off purchases, diagnostics, and category expansion into higher-value treatments such as weight loss and hormone health. Its strategic model is built around vertical integration, proprietary data from platform interactions, and geographic expansion beyond the United States through acquisitions and launches in Europe and Canada, with broader international ambitions stated by management.
Company news briefing
Briefing updated:
Hims & Hers continues to prioritise international expansion through the Zava acquisition and corporate restructuring, though recent financial filings indicate ongoing shifts in profitability. Regulatory and legal pressures have intensified following an FTC lawsuit and subsequent securities class action alleging the unanalysed sharing of sensitive customer health data with major advertising platforms. Meanwhile, strong consumer adherence to prescription product formulations like the Biotin + Minoxidil gummy supports robust full-year revenue guidance between $2.8 billion and $3 billion.
Business model & monetisation
Hims & Hers monetises primarily through recurring consumer subscriptions tied to treatment plans, prescription medications, and ongoing access to care. It also captures revenue from consultation-related services, one-off product purchases, diagnostics, and prescription fulfilment. Commercially, the model blends subscription billing, service fees embedded in care pathways, and product margin on delivered pharmaceuticals and wellness treatments. Growth is reinforced by upsell across multiple condition categories and expansion into higher-value speciality treatments.
- Recurring treatment subscriptions
- Subscription billing for ongoing care, prescriptions, and delivery
- Prescription fulfilment and medication sales
- Retail margin on pharmaceuticals and wellness products
- Consultation and care access
- Service fee embedded in telehealth visits and treatment workflows
- Diagnostics and testing
- One-time sale or episodic service revenue
Products & capabilities
No products with linked sources are available in this view.
Products & market categories
Recent recorded signals
Dates refer to the source publication. Older entries are historical context, not evidence of a new event.
Hims & Hers Securities Fraud Class Action Filed
Privacy · Recorded impact score: 2/5
A securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) in the U.S. District Court for the Northern District of California. The suit alleges the telehealth company failed to disclose that it shared sensitive health information with third-party advertising platforms, including Snap and Meta (Facebook), and misled consumers about its billing practices, including premature prescription charges. The FTC filed a related lawsuit on July 29, 2026, prompting a 14.73% stock decline to $25.00. Investors who purchased HIMS securities between August 4, 2025, and July 29, 2026, have until November 2, 2026, to apply as lead plaintiff. The case, Velanki v. Hims & Hers Health, Inc. et al., is being publicized by law firms including Kahn Swick & Foti, Kessler Topaz Meltzer & Check, and the Law Offices of Howard G. Smith.
- FTC sued Hims & Hers for sharing sensitive health data with advertising platforms and deceptive billing practices.
- Hims & Hers stock dropped $4.32 (14.73%) to $25.00 on July 29, 2026.
Hims & Hers' Prescription Gummy Drives High Adherence
Product Design / D2C Pharmaceutical Convergence · Recorded impact score: 2/5
Hims & Hers launched a prescription Biotin + Minoxidil gummy for hair growth in June 2025. One year after launch the company surveyed 300 customers and reported an 88% daily adherence rate; 79% cited the green apple flavor as a reason for continued use and about two-thirds said the frosted glass jar packaging improved their experience. The article describes manufacturing and formulation challenges in creating a prescription-grade gummy and notes Hims & Hers' broader strategy of using design to de-stigmatize prescription products. The company reported $608.1 million in Q1 revenue in its May earnings report and gave full-year guidance of $2.8 billion to $3 billion.
- Hims & Hers launched the Biotin + Minoxidil Gummy (prescription) in June 2025.
- Hims & Hers surveyed 300 customers and reported an 88% daily adherence rate for the gummy.
FTC sues Hims & Hers over sharing health data
Privacy · Recorded impact score: 4/5
The U.S. Federal Trade Commission has sued telehealth and consumer healthcare company Hims & Hers, alleging the company shared customers’ sensitive medical and healthcare information with advertisers and major tech firms including Meta and Snap, and misled consumers about its privacy practices. The FTC's complaint, filed in a California federal court, says Hims & Hers placed pixel-sized trackers from Meta, Snap, Microsoft, Pinterest, Reddit and X that captured and shared users’ health information. The complaint also accuses the company of deceptive billing practices and creating barriers to cancellation. Hims & Hers responded that its privacy policy enables users to choose how their data is used and said it will defend against the allegations. The action continues a pattern of FTC enforcement against healthcare-related companies over third-party web trackers.
- The Federal Trade Commission filed a lawsuit accusing Hims & Hers of sharing customers’ medical and healthcare information with advertisers and tech companies, including Meta and Snap.
- The FTC alleged Hims & Hers placed pixel-sized trackers provided by Meta, Snap, Microsoft, Pinterest, Reddit, and X that captured and shared users’ health information.
8-K Financial Filing Analysis for Hims & Hers Health, Inc.
financials · Recorded impact score: 3.9/5
Hims & Hers Health, Inc. announced that its subsidiaries, XeCare LLC and Apostrophe Pharmacy LLC, entered into a Master Receivables Purchase Agreement (RPA) with JPMorgan Chase Bank, N.A., providing a facility limit of up to $400 million for eligible receivables. The facility carries an initial 364-day term with renewable one-year extension options. In support of the arrangement, Hims & Hers executed a Performance Undertaking guaranteeing the performance of the seller subsidiaries' operational obligations without guaranteeing receivables collectability or creditworthiness. In tandem, the company entered into Amendment No. 4 to its Revolving Credit and Guaranty Agreement with JPMorgan Chase to establish a new $400 million permitted indebtedness basket and update collateral terms to facilitate the RPA. This financing structure enhances working capital flexibility and operational liquidity to support continued expansion across its direct-to-consumer healthcare and pharmacy operations.
- Subsidiaries XeCare LLC and Apostrophe Pharmacy LLC entered into a Master Receivables Purchase Agreement (RPA) with JPMorgan Chase Bank, N.A. featuring a $400 million facility limit and an initial 364-day term.
- Hims & Hers Health entered into a Performance Undertaking guaranteeing subsidiary performance obligations under the RPA, excluding collectability and creditworthiness guarantees.
Grindr’s Two New Products Boost Stock Appeal
Financials · Recorded impact score: 2/5
Morgan Stanley upgraded Grindr to overweight and raised its price target to $18, citing two products the bank believes can materially improve monetization. Analyst Nathan Feather highlighted an "ultra-premium" subscription tier called Edge (being tested in select U.S. markets with pricing cited around $100–$500 per month) and a telehealth offering named Woodwork, launched last year and described as a competitor to Hims. Morgan Stanley said Grindr has strong engagement and profitability potential and now expects the company could grow revenue at an 18% CAGR from 2025–2028. The stock has been weak over the prior year but shows limited analyst coverage; LSEG data indicates four of five covering analysts rate it a buy.
- Morgan Stanley upgraded Grindr to overweight and raised its price target to $18 (from $15).
- Grindr is testing an "ultra-premium" subscription tier called Edge in select U.S. markets, with reported pricing of roughly $100–$500 per month.
Explore company relationships
Questions about Hims & Hers
What is Hims & Hers?
Hims & Hers is a public consumer telehealth platform that connects patients with licensed providers and delivers prescription treatments, diagnostics, and ongoing subscription care.
Who uses Hims & Hers?
Individual consumers use Hims & Hers for discreet, convenient access to online consultations, prescription medications, weight management, mental health, dermatology, hormone health, and related care.
How does Hims & Hers make money?
It makes money mainly from recurring subscriptions, prescription fulfilment, medication sales, consultation-related services, diagnostics, and cross-sell across treatment categories.
Sources & coverage
This profile uses public, official and technically observable information. Missing information does not prove that a product or relationship does not exist. The list below does not imply that every profile statement has been verified.
13 publicly documented primary sources and citations linked across the market graph.
Continue your research on Hims & Hers
Explorer includes additional company details, a Watchlist for up to 25 companies and your personal Strategic Intelligence Agent. It monitors your market daily and delivers tailored briefings with clear strategic context whenever relevant news occurs.
Free, with no time limit.